西妥昔单抗- ir700偶联物光免疫治疗引起的间质性肺炎

IF 1.5 4区医学 Q2 OTORHINOLARYNGOLOGY

Auris Nasus Larynx Pub Date : 2025-06-18 DOI:10.1016/j.anl.2025.06.008

Yu Suekata , Tomoyuki Otsuka , Takuya Asai , Kenta Uemura , Yoshiki Kojitani , Mizuki Korematsu , Koji Kitamura , Junji Miyabe , Minako Nishio , Toshihiro Kudo , Takashi Fujii

{"title":"西妥昔单抗- ir700偶联物光免疫治疗引起的间质性肺炎","authors":"Yu Suekata , Tomoyuki Otsuka , Takuya Asai , Kenta Uemura , Yoshiki Kojitani , Mizuki Korematsu , Koji Kitamura , Junji Miyabe , Minako Nishio , Toshihiro Kudo , Takashi Fujii","doi":"10.1016/j.anl.2025.06.008","DOIUrl":null,"url":null,"abstract":"<div><div>Photoimmunotherapy (PIT) is a newly developed cancer therapy that uses the tumor-targeted monoclonal antibody cetuximab conjugated to the photoabsorbing dye IR700. It is currently approved for the treatment of unresectable, locally advanced, or locoregionally recurrent head and neck cancers in Japan. However, data regarding the clinical safety of PIT are currently limited in the literature. Herein, we report the case of a 70-year-old man with nasopharyngeal squamous cell carcinoma who developed interstitial pneumonia after receiving PIT. He developed a fever 3 days after PIT, and computed tomography revealed ground-glass opacities in both lungs. He was diagnosed with drug-induced interstitial pneumonia, and subsequently responded well to prednisolone therapy. This case highlights the potential risk of interstitial pneumonia associated with the cetuximab-IR700 conjugate used in PIT. Clinicians should consider the possibility of interstitial lung disease whenever fever persists following PIT. Further studies are warranted to fully characterize the safety profile of PIT.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 4","pages":"Pages 394-397"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interstitial pneumonia caused by Photoimmunotherapy with cetuximab-IR700 conjugate\",\"authors\":\"Yu Suekata , Tomoyuki Otsuka , Takuya Asai , Kenta Uemura , Yoshiki Kojitani , Mizuki Korematsu , Koji Kitamura , Junji Miyabe , Minako Nishio , Toshihiro Kudo , Takashi Fujii\",\"doi\":\"10.1016/j.anl.2025.06.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Photoimmunotherapy (PIT) is a newly developed cancer therapy that uses the tumor-targeted monoclonal antibody cetuximab conjugated to the photoabsorbing dye IR700. It is currently approved for the treatment of unresectable, locally advanced, or locoregionally recurrent head and neck cancers in Japan. However, data regarding the clinical safety of PIT are currently limited in the literature. Herein, we report the case of a 70-year-old man with nasopharyngeal squamous cell carcinoma who developed interstitial pneumonia after receiving PIT. He developed a fever 3 days after PIT, and computed tomography revealed ground-glass opacities in both lungs. He was diagnosed with drug-induced interstitial pneumonia, and subsequently responded well to prednisolone therapy. This case highlights the potential risk of interstitial pneumonia associated with the cetuximab-IR700 conjugate used in PIT. Clinicians should consider the possibility of interstitial lung disease whenever fever persists following PIT. Further studies are warranted to fully characterize the safety profile of PIT.</div></div>\",\"PeriodicalId\":55627,\"journal\":{\"name\":\"Auris Nasus Larynx\",\"volume\":\"52 4\",\"pages\":\"Pages 394-397\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Auris Nasus Larynx\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0385814625000963\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Auris Nasus Larynx","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0385814625000963","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

光免疫疗法（PIT）是一种新开发的癌症治疗方法，它使用靶向肿瘤的单克隆抗体西妥昔单抗结合光吸收染料IR700。目前在日本，它被批准用于治疗不可切除、局部晚期或局部复发的头颈癌。然而，目前文献中关于PIT临床安全性的数据有限。在此，我们报告一位70岁男性鼻咽鳞状细胞癌患者在接受PIT治疗后发生间质性肺炎。他在PIT后3天出现发烧，计算机断层扫描显示双肺磨玻璃样混浊。他被诊断为药物性间质性肺炎，随后对强的松龙治疗反应良好。该病例强调了与PIT中使用的西妥昔单抗- ir700结合物相关的间质性肺炎的潜在风险。当PIT术后持续发热时，临床医生应考虑肺间质性疾病的可能性。需要进一步的研究来充分描述PIT的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interstitial pneumonia caused by Photoimmunotherapy with cetuximab-IR700 conjugate

Photoimmunotherapy (PIT) is a newly developed cancer therapy that uses the tumor-targeted monoclonal antibody cetuximab conjugated to the photoabsorbing dye IR700. It is currently approved for the treatment of unresectable, locally advanced, or locoregionally recurrent head and neck cancers in Japan. However, data regarding the clinical safety of PIT are currently limited in the literature. Herein, we report the case of a 70-year-old man with nasopharyngeal squamous cell carcinoma who developed interstitial pneumonia after receiving PIT. He developed a fever 3 days after PIT, and computed tomography revealed ground-glass opacities in both lungs. He was diagnosed with drug-induced interstitial pneumonia, and subsequently responded well to prednisolone therapy. This case highlights the potential risk of interstitial pneumonia associated with the cetuximab-IR700 conjugate used in PIT. Clinicians should consider the possibility of interstitial lung disease whenever fever persists following PIT. Further studies are warranted to fully characterize the safety profile of PIT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Auris Nasus Larynx 医学-耳鼻喉科学

CiteScore

3.40

自引率

5.90%

发文量

169

审稿时长

30 days

期刊介绍： The international journal Auris Nasus Larynx provides the opportunity for rapid, carefully reviewed publications concerning the fundamental and clinical aspects of otorhinolaryngology and related fields. This includes otology, neurotology, bronchoesophagology, laryngology, rhinology, allergology, head and neck medicine and oncologic surgery, maxillofacial and plastic surgery, audiology, speech science. Original papers, short communications and original case reports can be submitted. Reviews on recent developments are invited regularly and Letters to the Editor commenting on papers or any aspect of Auris Nasus Larynx are welcomed. Founded in 1973 and previously published by the Society for Promotion of International Otorhinolaryngology, the journal is now the official English-language journal of the Oto-Rhino-Laryngological Society of Japan, Inc. The aim of its new international Editorial Board is to make Auris Nasus Larynx an international forum for high quality research and clinical sciences.